Esomeprazole

Drugs for peptic ulcer and GORD. Proton pump inhibitors

ATC code: A02BC05

Brand names: Nexium 24HR, Nexium

Updated 24 Sep 2026 · Methodology

Indications

Functional dyspepsia

First line

Esomeprazole is a proton pump inhibitor, and PPIs are first-line for functional dyspepsia (/CAG 2017). Cochrane confirms a PPI advantage over placebo (NNT about 11), and esomeprazole has positive RCTs. Use a short course with review at 4 to 8 weeks; with alarm features (weight loss, dysphagia, bleeding, new onset over age 50) endoscopy comes first. Long-term use without an indication is undesirable.

Sources

ICD-10: K30 · ICD-11: DD90.3

Gastroesophageal reflux disease

First line

First-line therapy for GERD in adults and adolescents. CG184 (2014, updated 2019) and 2022 recommend PPIs as the baseline GERD therapy, with dose chosen by esophagitis severity. Erosive esophagitis is treated for 8 weeks, non-erosive disease for 4 weeks with reassessment. Esomeprazole shows efficacy comparable to other PPIs at equivalent doses; at 40 mg it outperforms omeprazole 20 mg in healing of severe erosive esophagitis.

After the course, the patient attempts withdrawal or switches to on-demand dosing. Continuous use beyond 8 weeks is reviewed every 6–12 months.

Sources

ICD-10: K21 · ICD-11: DA22

Helicobacter pylori infection

First line

Esomeprazole is one of the PPIs used in H. pylori eradication. Maastricht VI/Florence 2022 and 2017 recommend triple or bismuth quadruple therapy for 14 days. Esomeprazole 40 mg twice daily within the regimen provides acid suppression that supports antibiotic activity and concentration stability in the stomach.

Sources

ICD-10: B98.0 · ICD-11: DA42.1

Peptic ulcer disease

First line

Esomeprazole is used for gastric and duodenal ulcers in adults. Standard dose 20–40 mg daily for 4–8 weeks. PPIs accelerate healing and reduce recurrence. In H. pylori-associated ulcer, esomeprazole is part of eradication therapy. In NSAID-related ulcers, the NSAID is discontinued and a PPI course is given with reassessment in 4–8 weeks.

Sources

ICD-10: K25 · ICD-11: DA60

Barrett esophagus

First line

In Barrett esophagus, PPIs are prescribed lifelong to suppress acid reflux and reduce metaplasia progression. 2022 supports continuous PPI therapy in confirmed Barrett esophagus. Adenocarcinoma prevention data are observational; randomized evidence of cancer risk reduction is lacking, but reflux control remains standard practice.

Sources

ACG: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (2022)

ICD-10: K22.7 · ICD-11: DA23.0

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

PPI for NSAID gastric prophylaxis in low-risk patients

Not recommended

PPI prophylaxis is not indicated in patients without risk factors for NSAID-induced gastropathy. Risk factors: age ≥ 65, history of peptic ulcer, history of GI bleeding, concurrent glucocorticoids or anticoagulants, high-dose or combined NSAID use, chronic kidney disease. Routine PPI «cover» without these factors is an overuse category.

Sources

ACG: ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (2022)

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

The S-enantiomer of omeprazole, specifically and irreversibly inhibits the H+/K+-ATPase (proton pump) of gastric parietal cells. Reduces basal and stimulated hydrochloric acid secretion by 80–95% with daily dosing. The advantage over omeprazole is more consistent pharmacokinetics: the S-enantiomer is less dependent on CYP2C19 metabolism and less affected by genetic variability. With daily dosing, a steady antisecretory effect is reached by days 3–5.

Safety

Contraindications

Hypersensitivity to esomeprazole or substituted benzimidazoles
Co-administration with rilpivirine
Age under 1 year for most formulations

Serious adverse effects

Acute interstitial nephritis
Hypomagnesemia with seizures and arrhythmias on long-term therapy
Anaphylaxis (rare)
Subacute cutaneous lupus erythematosus
Increased risk of Clostridioides difficile infection

Common adverse effects

Headache
Diarrhea, constipation, flatulence
Nausea, abdominal discomfort
Dry mouth

Uncommon adverse effects

Rash, pruritus
Insomnia, dizziness
ALT/AST increase
Peripheral edema

Pregnancy: can you take Esomeprazole?

AEMPS summary of product characteristics (section 4.6): clinical data on pregnancies exposed to esomeprazole are insufficient, but data on 300 to 1,000 pregnancies indicate that esomeprazole does not cause malformations or fetal or neonatal toxicity. Epidemiological data from a larger number of pregnancies exposed to the racemic mixture, omeprazole, indicate no fetotoxic effects or malformations. Animal studies with esomeprazole and with the racemic mixture indicate no direct or indirect harmful effects on embryofetal development, pregnancy, parturition or postnatal development. Esomeprazole is prescribed to pregnant women with caution.

Breastfeeding: can you take Esomeprazole?

Passes into breast milk in minimal amounts. LactMed classifies it as compatible with breastfeeding. Monitor the infant for gastrointestinal symptoms.

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Taken 30–60 minutes before a meal, usually half an hour before breakfast. Fasting absorption is maximal, and parietal cell activation coincides with the peak of acid production. Capsules and tablets are swallowed whole without chewing so the enteric coating ensures small intestinal absorption.

Monitoring

With long-term use (over 1 year), monitor serum magnesium and vitamin B12 annually. In older patients and in osteoporosis, assess bone density and consider calcium and vitamin D adjustment. After 4–8 weeks of treatment for GERD or peptic ulcer, evaluate response and consider step-down or withdrawal.

Special situations

Abrupt withdrawal after prolonged therapy can cause rebound hyperacidity with return of heartburn in 2–7 days – even in patients without prior symptoms. Tapering is gradual: half-dose, every other day, then on-demand H2 blockers. Co-administration with clopidogrel does not affect cardiovascular outcomes per the COGENT RCT; routine PPI withdrawal during dual antiplatelet therapy is not warranted.

Drug interactions

Reduces absorption of drugs that require an acidic gastric environment: ketoconazole, itraconazole, atazanavir, erlotinib, iron preparations. With high-dose methotrexate – prolonged elimination and increased toxicity. Not combined with rilpivirine.

Common myths

Myth: «PPIs can be taken for years without consequences». Fact: long-term therapy is linked to B12 and magnesium deficiency, increased fracture and C. difficile infection risk. Prescriptions must be justified, and duration reviewed.

Myth: «esomeprazole is stronger than omeprazole». Fact: 40 mg esomeprazole is roughly equivalent to 40 mg omeprazole but more pharmacokinetically stable. The advantage is predictability, not «power».

Myth: «PPIs cure the cause of reflux». Fact: PPIs suppress acid but do not eliminate the cause. After withdrawal, symptoms often return.

Drug–nutrient interactions

Magnesium

PPIs reduce magnesium absorption in the small intestine. Long-term therapy leads to hypomagnesemia in some patients, with clinical manifestations: seizures, tetany, arrhythmias, tremor. issued a dedicated warning in 2011. Monitor magnesium every 12 months; every 3–6 months with concurrent diuretics.

Source: AEMPS: Ficha técnica de Esomeprazol (2024)

Vitamin B12

PPIs reduce gastric acidity and impair release of dietary B12 from proteins. Long-term use (>2 years) raises B12 deficiency risk 1.5–2 fold. Check B12 levels in PPI courses longer than 12 months, especially in the elderly.

Vitamin B12

Long-term (over 2 years) suppression of gastric secretion reduces release of B12 from dietary proteins, leading to subclinical or clinical deficiency in some patients. Annual serum B12 monitoring is recommended for continuous therapy beyond 2 years; oral or parenteral replacement is prescribed at levels below 200 pg/mL.

Source: AEMPS: Ficha técnica de Esomeprazol (2024)

Iron

Iron salts (sulfate, fumarate) require gastric acid to convert to Fe2+ and be absorbed. On PPI therapy their bioavailability falls by 20–50%. In iron-deficiency anemia in PPI users, parenteral forms or chelated iron are preferred.

Source: AEMPS: Ficha técnica de Esomeprazol (2024)

Calcium

Calcium carbonate absorption is acid-dependent, and long-term PPI use lowers its bioavailability. Meta-analyses link long-term (> 1 year) PPI use to a modest increase in hip and vertebral fracture risk, mainly in older adults. For PPI users at osteoporosis risk, organic calcium salts (citrate) that do not require an acidic environment are preferred.

Source: AEMPS: Ficha técnica de Esomeprazol (2024)

Drug–drug interactions

6 pairs found. Sorted from critical to minor.

MajorCitalopramSSRI (selective serotonin reuptake inhibitor)

Mechanism

Esomeprazole is the S-isomer of omeprazole and the same CYP2C19 inhibitor; CYP2C19 handles about 38% of citalopram metabolism. In therapeutic drug monitoring data, citalopram serum levels were about a third higher with esomeprazole (+33%). The caps citalopram at 20 mg/day with CYP2C19 inhibitors.

Symptoms

QT prolongation on the ECG. Clinically: dizziness, palpitations, syncope. Severe cases progress to torsade de pointes. The risk is higher with bradycardia, hypokalaemia, hypomagnesaemia, congenital long QT syndrome, recent myocardial infarction and decompensated heart failure.

Management

The pair is not banned, but the citalopram dose is capped: with esomeprazole or another CYP2C19 inhibitor, no more than 20 mg/day (US Food and Drug Administration () citalopram label). The esomeprazole SmPC names citalopram among drugs that may need a lower dose, especially when esomeprazole is taken on demand, and the Spanish citalopram SmPC asks for caution with this combination. Potassium and magnesium are corrected before citalopram is started, and in patients at risk of electrolyte disturbances they are checked at baseline and periodically (citalopram labels). If signs of arrhythmia appear, citalopram is stopped and an electrocardiogram (ECG) is done (citalopram SmPC).

Sources

Pair details →Citalopram →

MajorClopidogrelAntiplatelet agents – P2Y12 receptor inhibitors

Mechanism

Esomeprazole inhibits CYP2C19, the key enzyme that converts clopidogrel to its active metabolite. Active clopidogrel levels fall by about 35%, weakening antiplatelet effect.

Symptoms

The patient feels no symptoms – the weakened antiplatelet effect is silent. The combination raises recurrent myocardial infarction and stent thrombosis risk in patients with prior stenting or acute coronary syndrome.

Management

Replace esomeprazole with pantoprazole (minimal CYP2C19 impact). Among other PPIs, rabeprazole is an alternative. If a PPI is not required, switch to famotidine (H2-blocker) or stop acid suppression.

Sources

Pair details →Clopidogrel →

MajorMethotrexateAntimetabolites, folic acid analogues

Mechanism

Proton pump inhibitors block the renal BCRP transporter and reduce methotrexate clearance. At high oncologic doses, risk of delayed elimination and severe toxicity.

Symptoms

Mouth ulcers (mucositis), nausea, diarrhoea, hair loss. Blood counts fall: leukocytes, platelets, erythrocytes. Severe cases: fatal pancytopenia, nephrotoxicity.

Management

With high-dose (oncology) methotrexate, the Spanish label requires avoiding proton pump inhibitors, especially in renal impairment. Withhold esomeprazole for the course and use an H2-receptor antagonist such as famotidine for gastric protection. With low-dose methotrexate (rheumatology, psoriasis) the combination is possible, but the labels warn about methotrexate accumulation, so monitor blood counts, creatinine and signs of toxicity such as mouth ulcers and diarrhoea, with extra care in reduced kidney function.

Sources

Pair details →Methotrexate →

MajorTacrolimusCalcineurin inhibitor (immunosuppressant)

Mechanism

Esomeprazole inhibits CYP2C19. Tacrolimus is minimally metabolised by CYP2C19, but in patients with slow metabolism (CYP2C19 genetic polymorphism) this route becomes the main one. In such patients tacrolimus plasma levels rise.

Symptoms

Acute nephrotoxicity: rising creatinine and falling glomerular filtration rate. Tremor, headache, hypertension, hyperglycaemia, hyperkalaemia. In transplant patients: accelerated graft function decline.

Management

In most patients, no clinically significant effect. In East Asian patients (high frequency of CYP2C19 slow metabolisers), alternative PPIs: pantoprazole or rabeprazole (weaker CYP2C19 effect). Check tacrolimus trough (C0) 1 week after starting esomeprazole.

Sources

Pair details →Tacrolimus →

ModerateAtorvastatinHMG-CoA reductase inhibitors (statins)

Mechanism

Esomeprazole weakly affects CYP3A4 (mainly via CYP2C19). Atorvastatin levels are essentially unchanged. DDInter notes rare myalgia.

Symptoms

Usually no changes. Rare muscle pain cases, especially in patients with myopathy risk factors.

Management

The combination is acceptable without dose change. In patients with myopathy risk factors (older age, chronic kidney disease, hypothyroidism), check creatine kinase on muscle symptoms.

Sources

FDA: Lipitor (atorvastatin) prescribing information (2017)

Pair details →Atorvastatin →

ModerateCyanocobalaminVitamins. Haemopoietic stimulants

Mechanism

Esomeprazole suppresses gastric acidity, reducing release of B12 from food (which requires HCl and pepsin). With over 2 years of therapy, B12 deficiency risk is reported.

Symptoms

Fatigue, pallor, paraesthesias in hands and feet, gait instability, memory decline. Develops over 2–4 years of unrecognised therapy.

Management

On long-term PPIs (over 2 years), check B12 yearly. Oral cyanocobalamin tablets or drops can be given regardless of acidity (passive diffusion absorption at high doses). Alternative: H2-blockers (famotidine) for short-term acid suppression.

Sources

PubMed: Metformin use and vitamin B12 deficiency: a systematic review and meta-analysis (2020)

Pair details →Cyanocobalamin →

Label mentions25 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

MajorAtazanavir
«Inhibidores de la Proteasa: Para el atazanavir y el nelfinavir, se ha comunicado una disminución de los niveles plasmáticos cuando se administran junto con omeprazol, por lo tanto, no se recomienda…»
AEMPS, section 4.5 · Open on CIMA
MajorClopidogrel
«Clopidogrel: En los estudios observacionales y clínicos se han registrado datos inconsistentes sobre las implicaciones clínicas de esta interacción PK/PD en relación a los acontecimientos…»
AEMPS, section 4.5 · Open on CIMA
MajorTacrolimus
«Tacrolimus: Se ha notificado un aumento de los niveles séricos de tacrolimus en la administración concomitante con esomeprazol. Se debe realizar un aumento del control de las concentraciones de…»
AEMPS, section 4.5 · Open on CIMA
ModerateCitalopram
«Medicamentos metabolizados por CYP2C19: Esomeprazol inhibe CYP2C19, el principal enzima metabolizador de esomeprazol. Por tanto, cuando se combina esomeprazol con fármacos metabolizados por CYP2C19…»
AEMPS, section 4.5 · Open on CIMA
ModerateClarithromycin
«Medicamentos que inhiben el CYP2C19 y/o CYP3A4: Esomeprazol es metabolizado por CYP2C19 y CYP3A4. La administración concomitante de esomeprazol y un inhibidor de CYP3A4, claritromicina (500 mg dos…»
AEMPS, section 4.5 · Open on CIMA
ModerateDiazepam
«Medicamentos metabolizados por CYP2C19: Esomeprazol inhibe CYP2C19, el principal enzima metabolizador de esomeprazol. Por tanto, cuando se combina esomeprazol con fármacos metabolizados por CYP2C19…»
AEMPS, section 4.5 · Open on CIMA
ModerateDigoxin
«Medicamentos con absorción pH-dependiente: La supresión del ácido gástrico durante el tratamiento con esomeprazol y otros IBPs, puede disminuir o aumentar la absorción de medicamentos con una…»
AEMPS, section 4.5 · Open on CIMA
ModerateItraconazole
«Medicamentos con absorción pH-dependiente: La supresión del ácido gástrico durante el tratamiento con esomeprazol y otros IBPs, puede disminuir o aumentar la absorción de medicamentos con una…»
AEMPS, section 4.5 · Open on CIMA
ModerateKetoconazole
«Medicamentos con absorción pH-dependiente: La supresión del ácido gástrico durante el tratamiento con esomeprazol y otros IBPs, puede disminuir o aumentar la absorción de medicamentos con una…»
AEMPS, section 4.5 · Open on CIMA
ModerateMethotrexate
«Metotrexato: Se ha notificado el aumento de los niveles de metotrexato en algunos pacientes cuando se administra conjuntamente con IBPs. Se debe considerar una retirada temporal de esomeprazol…»
AEMPS, section 4.5 · Open on CIMA
ModeratePhenytoin
«Medicamentos metabolizados por CYP2C19: Esomeprazol inhibe CYP2C19, el principal enzima metabolizador de esomeprazol. Por tanto, cuando se combina esomeprazol con fármacos metabolizados por CYP2C19…»
AEMPS, section 4.5 · Open on CIMA
ModerateVoriconazole
«Medicamentos que inhiben el CYP2C19 y/o CYP3A4: Esomeprazol es metabolizado por CYP2C19 y CYP3A4. La administración concomitante de esomeprazol y un inhibidor de CYP3A4, claritromicina (500 mg dos…»
AEMPS, section 4.5 · Open on CIMA
ModerateWarfarin
«Warfarina: En un ensayo clínico, la administración concomitante de 40 mg de esomeprazol a pacientes tratados con warfarina mostró que los tiempos de coagulación permanecieron dentro del rango…»
AEMPS, section 4.5 · Open on CIMA
Amoxicillin
«Amoxicilina y quinidina: Se ha demostrado que esomeprazol no presenta efectos clínicamente relevantes sobre la farmacocinética de amoxicilina o quinidina.»
AEMPS, section 4.5 · Open on CIMA
Darunavir
«Inhibidores de la Proteasa: Para el saquinavir (con ritonavir concomitante), se han comunicado niveles plasmáticos aumentados (80-100%) durante el tratamiento concomitante con omeprazol (40 mg una…»
AEMPS, section 4.5 · Open on CIMA
Naproxen
«Naproxeno o rofecoxib: Durante los estudios a corto plazo que evaluaron la administración concomitante de esomeprazol y naproxeno o rofecoxib no se ha identificado ninguna interacción farmacocinética…»
AEMPS, section 4.5 · Open on CIMA
Quinidine
«Amoxicilina y quinidina: Se ha demostrado que esomeprazol no presenta efectos clínicamente relevantes sobre la farmacocinética de amoxicilina o quinidina.»
AEMPS, section 4.5 · Open on CIMA
Rifampicin
«Medicamentos que induc en el CYP2C19 y/o CYP3A4: Los medicamentos que inducen el CYP2C19 o el CYP3A4 o ambos (como la rifampicina y la hierba de San Juan) puede conducir a la disminución de los…»
AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

MajorClopidogrel
«En ensayos clínicos y observacionales, se han notificado datos inconsistentes sobre las implicaciones clínicas de esta interacción farmacocinética (PK)/farmacodinámica (PD) en términos de…»
AEMPS, section 4.5 · Open on CIMA
MajorClopidogrel
«CYP2C19 Inhibitors: Avoid concomitant use of clopidogrel with omeprazole or esomeprazole. In clinical studies, omeprazole was shown to reduce significantly the antiplatelet activity of clopidogrel…»
FDA, section 7 · Open on DailyMed
ModerateCitalopram
«Cimetidina: La administración conjunta de escitalopram (el enantiómero activo de citalopram) con omeprazol 30 mg una vez al día (un inhibidor de la CYP2C19), produjo un incremento moderado…»
AEMPS, section 4.5 · Open on CIMA
ModerateDigoxin
«Pharmacokinetic Drug Interactions: Alprazolam, azithromycin, cyclosporine, diclofenac, diphenoxylate, epoprostenol, esomeprazole, ibuprofen, ketoconazole, lansoprazole, metformin, omeprazole Measure…»
FDA, section 7 · Open on DailyMed
ModerateEscitalopram
«Influencia de otros medicamentos en la farmacocinética de escitalopram: Por lo tanto, hay que tener precaución cuando se utiliza junto con inhibidores de la enzima CYP2C19 (ej. omeprazol…»
AEMPS, section 4.5 · Open on CIMA
Diazepam
«Inhibidores enzimáticos: El inhibidor de la bomba de protones, omeprazol, inhibidor de CYP3A4 y CYP2C19, administrado a dosis de 20 mg al día incrementa el AUC de diazepam en un 40% y la semivida en…»
AEMPS, section 4.5 · Open on CIMA
Ulipristal acetate
«Medicamentos que afectan al pH gástrico: La administración de acetato de ulipristal (comprimido de 10 mg) junto con el inhibidor de la bomba de protones esomeprazol (20 mg diarios durante 6 días) dio…»
AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Esomeprazole used for?

Esomeprazole is evaluated for the following indications with varying evidence strength: Helicobacter pylori infection (evidence tier A), Peptic ulcer disease (evidence tier A), Gastroesophageal reflux disease (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Esomeprazole?

Common side effects of Esomeprazole (≥ 1 in 100): Headache, Diarrhea, constipation, flatulence, Nausea, abdominal discomfort, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Esomeprazole safe during pregnancy?

Is Esomeprazole compatible with breastfeeding?

Passes into breast milk in minimal amounts. LactMed classifies it as compatible with breastfeeding. Monitor the infant for gastrointestinal symptoms.

Who should not take Esomeprazole?

Esomeprazole is contraindicated in: Hypersensitivity to esomeprazole or substituted benzimidazoles; Co-administration with rilpivirine; Age under 1 year for most formulations. Full list in the Safety section.

PPIs can be taken for years without consequences

long-term therapy is linked to B12 and magnesium deficiency, increased fracture and C. difficile infection risk. Prescriptions must be justified, and duration reviewed.

esomeprazole is stronger than omeprazole

40 mg esomeprazole is roughly equivalent to 40 mg omeprazole but more pharmacokinetically stable. The advantage is predictability, not «power».

PPIs cure the cause of reflux

PPIs suppress acid but do not eliminate the cause. After withdrawal, symptoms often return.

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA
EMALabel dated 08/26/2013
FDA / DailyMedLabel dated 07/26/2024
GRLS

Other drugs in this group

Famotidine, Lansoprazole, Magnesium hydroxide, Mastic gum, Rabeprazole, Sodium alginate, Omeprazole, Pantoprazole